Beone Medicines Ltd (ONC) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Beone Medicines Ltd   (NASDAQ: ONC)


Beone Medicines Ltd's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Beone Medicines Ltd's ROI in the third quarter of 2026?
Beone Medicines Ltd achieved a return on average invested assets (ROI) of 13.17 % in its third quarter of 2026 a new company high.

ROI has improved compared to 10.32% in the second quarter of 2026, due to net income growth.

Within the Healthcare sector 46 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Sep 30 2026 quarter, so far to 899, from total ROI ranking in the second quarter of 2026 at 1512.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Investment Change TTM 64.34 % 64.46 % 48.29 % 29.85 % 9.99 %
Y / Y Net Income Change TTM 1235.63 % - - - -
Investment (TTM) in Millions 7,642 7,056 6,742 6,360 5,264
Return On Investment (TTM) 13.17 % 10.32 % 9.14 % 5.86 % 1.62 %
ONC's Overall Ranking # 899 # 1512 # 2098 # 2948 # 3219
Seq. Investment Change TTM 9.35 % 13.22 % 14.74 % 15.69 % 9.44 %
Seq. Net Income Change TTM 39.63 % 27.81 % 78.79 % 318.57 % -
Net Income (TTM) in Millions 916 656 513 287 69

ONC Company Profile >> Back to ONC Roi Comparisons >> See Annual ONC Return On Investment



Return On Investment ONC's Ranking
Within: No.
Industry # 17
Sector # 47
Overall # 899

Return On Investment Statistics
High Average Low
13.17 %
-27.68 %
-70.05 %
(Sep 30 2026)   (Jun 30 2017)



  News about Beone Medicines Ltd Return on Investment ROI

Unveiling New Horizons in Cancer Therapy The Transformative Potential of Sonrotoclax and TEVIMBRA in Modern Oncolog...

November 27, 2025

Biopharmaceutical advances continue to transform the landscape of cancer treatment, offering new hope where traditional therapies have fallen short. In this article, we delve into the latest developments surrounding BeOne Medicines Ltd. s promising oncological agents, sonrotoclax and TEVIMBRA, two compounds set to redefine treatment protocols for various challenging cancer types. Sonrotoclax: A New Dawn in Relapsed or Refractory Mantle Cell LymphomaBeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), globally recognized for its commitment to oncology, has announced significant strides with its investigative agent sonrotoclax, a potent BCL-2 inhibitor. This announcement comes in the wake of new drug application (NDA) submissions to the U.S. Food and Drug Administration (FDA) for its use in treating relapsed or refractory (R/R) mantle cell lymphoma (MCL).





Financial Statements
Beone Medicines Ltd's III. Quarter Investments $ 7,642 Millions ONC's Balance sheet
Beone Medicines Ltd's III. Quarter Income $ 385 Millions Quarterly ONC's Income Statement
ONC's Income by Division See ONC's Income by Division


ONC Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 6,360 3,706 3,995 4,911 7,046
Y / Y Investment Growth 71.61 % -7.24 % -18.64 % -30.31 % 55.7 %
Net Income in Millions 287 -645 -882 -2,004 -1,413
Y / Y Net Income Growth - - - - -
Annual Return On Investment 4.51 % -17.4 % -22.07 % -40.8 % -20.06 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 4.51 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ONC's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ONC's Competitors
Subscribers only: Roi for Beone Medicines Ltd's Suppliers
Subscribers only: Return On Investment for ONC's Customers

Other Ratios
ONC's Roa ONC's Inventory Turnover Ratio ONC's Growth Rates ONC's Dividend Statistics
ONC's Profitability Ratios ONC's Asset Turnover Ratio ONC's Dividend Growth
ONC's Roe ONC's Valuation Ratios ONC's Financial Strength Ratios ONC's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector ROI
Rallybio Corporation  36.04 %
Eli Lilly And Company  32.00 %
Caredx Inc   30.65 %
Zevra Therapeutics Inc   29.88 %
Acadia Pharmaceuticals Inc   26.89 %
Protalix Biotherapeutics inc   26.06 %
Standard Biotools Inc   23.91 %
Electromed Inc   23.41 %
Iradimed Corporation  22.98 %
Corcept Therapeutics Inc  22.08 %
Resmed Inc   21.10 %
Alector Inc   20.83 %
Chemed Corporation  20.46 %
Halozyme Therapeutics Inc   19.64 %
Pro dex Inc   19.11 %
Dexcom Inc   18.92 %
Illumina Inc   18.74 %
Denali Therapeutics Inc   17.88 %
West Pharmaceutical Services Inc   17.65 %
Healthcare Services Group Inc   17.18 %
Neurocrine Biosciences Inc   16.94 %
Krystal Biotech Inc   16.91 %
Vertex Pharmaceuticals Inc  16.63 %
Sanuwave Health Inc   16.50 %
Intuitive Surgical Inc   16.30 %
Hca Healthcare Inc   15.54 %
Kiniksa Pharmaceuticals International Plc  15.45 %
Amgen Inc   13.64 %
Carlisle Companies Incorporated  13.64 %
Bristol myers Squibb Company  13.59 %

Date modified: 2026-11-10T10:37:50+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.